Upadacitinib Drug Survival in the Management of Patients With Moderate to Severe Atopic Dermatitis: Real-Time Data From the Biogrid Database Registry

CONCLUSION: These findings indicate that Upadacitinib may offer a longer-lasting treatment option with good overall retention in ad management. Real-world data such as these provide crucial insights for dermatologists in choosing appropriate therapies, potentially enhancing patient satisfaction, adherence, and long-term outcomes. Further studies with larger sample sizes and diverse populations are recommended to validate these findings and guide treatment strategies.